Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma

Cancer Science

Volumn 108, Issue 5, 2017, Pages 1007-1012

  Maruyama, Dai ^a   Hatake, Kiyohiko ^b   Kinoshita, Tomohiro ^c   Fukuhara, Noriko ^d   Choi, Ilseung ^e   Taniwaki, Masafumi ^f   Ando, Kiyoshi ^g   Terui, Yasuhito ^b   Higuchi, Yusuke ^c   Onishi, Yasushi ^d   Abe, Yasunobu ^e   Kobayashi, Tsutomu ^f   Shirasugi, Yukari ^g   Tobinai, Kensei ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

^d TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e NATIONAL KYUSHU CANCER CENTER   (Japan)

^f KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^g TOKAI UNIVERSITY   (Japan)

Author keywords

Hodgkin lymphoma; immunotherapy; Japanese; nivolumab; programmed death 1

Indexed keywords

BRENTUXIMAB VEDOTIN; DRUG ANTIBODY; NIVOLUMAB; ANTIBODY CONJUGATE; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR;

ACNE; ADULT; AGED; ANEMIA; ANTIBODY DETECTION; ARTICLE; BACKACHE; CANCER REGRESSION; CANCER SURVIVAL; CATARACT; CLASSICAL HODGKIN LYMPHOMA; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; ENTEROCOLITIS; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; HYPONATREMIA; HYPOTHYROIDISM; INSULIN DEPENDENT DIABETES MELLITUS; INTERSTITIAL LUNG DISEASE; JAPANESE (PEOPLE); LYMPHOCYTOPENIA; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; RHINOPHARYNGITIS; SIDE EFFECT; SKIN CYST; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME; UPPER RESPIRATORY TRACT INFECTION; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; DISEASE FREE SURVIVAL; HODGKIN DISEASE; METABOLISM; MIDDLE AGED; PROCEDURES; REMISSION; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ASIAN CONTINENTAL ANCESTRY GROUP; DISEASE-FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGRAMMED CELL DEATH 1 RECEPTOR; REMISSION INDUCTION;

EID: 85019693131     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.13230     Document Type: Article

References (26)

1. Makita S, Maruyama D, Maeshima AM et al. Clinical features and outcomes of 139 Japanese patients with Hodgkin lymphoma. Int J Hematol 2016; 104: 233–44.
2. Ogura M, Itoh K, Kinoshita T et al. Phase II study of ABVd therapy for newly diagnosed clinical stage II–IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305). Int J Hematol 2010; 92: 713–24.
3. Kewalramani T, Nimer SD, Zelenetz AD et al. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2003; 32: 673–9.
4. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: Targeted drug delivery for cancer. Curr Opin Chem Biol 2010; 14: 529–37.
5. Alperovich A, Younes A. Targeting CD30 using brentuximab vedotin in the treatment of Hodgkin lymphoma. Cancer J 2016; 22: 23–6.
6. Younes A, Gopal AK, Smith SE et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012; 30: 2183–9.
7. Ogura M, Tobinai K, Hatake K et al. Phase I/II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma. Cancer Sci 2014; 105: 840–6.
8. Cheah CY, Chihara D, Horowitz S et al. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Ann Oncol 2016; 27: 1317–23.
9. Homet Moreno B, Ribas A. Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. Br J Cancer 2015; 112: 1421–7.
10. Jezeršek Novaković B. Checkpoint inhibitors in Hodgkin's lymphoma. Eur J Haematol 2016; 96: 335–43.
11. Sunshine J, Taube JM. PD-1/PD-L1 inhibitors. Curr Opin Pharmacol 2015; 23: 32–8.
12. Chen BJ, Chapuy B, Ouyang J et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 2013; 19: 3462–73.
13. Green MR, Monti S, Rodig SJ et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010; 116: 3268–77.
14. Paydas S, Bağir E, Seydaoglu G, Ercolak V, Ergin M. Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma. Ann Hematol 2015; 94: 1545–52.
15. Yamamoto R, Nishikori M, Kitawaki T et al. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 2008; 111: 3220–4.
16. Roemer MG, Advani RH, Ligon AH et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol 2016; 34: 2690–7.
17. Ansell SM, Lesokhin AM, Borrello I et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372: 311–9.
18. Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579–86.
19. Younes A, Santoro A, Shipp M et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: A multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 2016; 17: 1283–94.
20. Böll B, Görgen H, Fuchs M et al. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. J Clin Oncol 2013; 31: 1522–9.
21. Stamatoullas A, Brice P, Bouabdallah R et al. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: Frequent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol 2015; 170: 179–84.
22. Munakata W, Ohashi K, Yamauchi N, Tobinai K. Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma. Int J Hematol 2017; 105: 383–6.
23. Hughes J, Vudattu N, Sznol M et al. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care 2015; 38: e55–7.
24. Martin-Liberal J, Furness AJ, Joshi K, Peggs KS, Quezada SA, Larkin J. Anti-programmed cell death-1 therapy and insulin-dependent diabetes: A case report. Cancer Immunol Immunother 2015; 64: 765–7.
25. Miyoshi Y, Ogawa O, Oyama Y. Nivolumab, an anti-programmed cell death-1 antibody, induces fulminant type 1 diabetes. Tohoku J Exp Med 2016; 239: 155–8.
26. Okamoto M, Okamoto M, Gotoh K et al. Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy. J Diabetes Investig 2016; 7: 915–8.